AMLX Q3 2023: Discontinuation Rate Hits 40%, Spotlighting Persistency Challenge Ahead of Phoenix Data
Persistency, not new patient starts, defined AMLX’s Q3 as US discontinuation rates reached 40% at six months, sharply contrasting with 20% in Canada. The company’s launch momentum at top ALS centers is intact, but broadening adoption and improving therapy duration are now the primary levers for future growth. All eyes turn to the upcoming Phoenix trial as a pivotal catalyst for both commercial uptake and global expansion.
Summary
- Persistency Gap Emerges: US discontinuation rates expose a major hurdle for sustained growth.
- Commercial Focus Shifts: Expansion beyond ALS centers and clinician education now critical priorities.
- Phoenix Trial as Inflection: Q2 2024 data will determine trajectory for adoption and global approvals.
Business Overview
Amelix Pharmaceuticals (AMLX) develops and commercializes therapies for neurodegenerative diseases, with its lead product, Relivrio, an oral ALS treatment, generating nearly all current revenue. The business is anchored in the US ALS market, with expansion efforts underway in Canada and select international markets. AMLX’s pipeline includes late-stage trials for additional neurodegenerative indications and next-generation formulations.
Performance Analysis
The company reported strong top-line revenue growth, driven by Relivrio’s continued uptake at major US ALS centers. Approximately 3,900 patients were on therapy at quarter-end, up only modestly from the prior quarter, reflecting a pronounced slowdown in net new patient adds. This deceleration was attributed to a rise in discontinuation rates, with just 60% of US patients remaining on therapy at six months versus 80% in Canada. The gap underscores the challenge of maintaining persistency in a decentralized US healthcare system.
Gross-to-net adjustments remained below long-term expectations, aided by lower chargebacks and rebates, while cost of goods sold (COGS) was tightly managed at 5% of net revenues. SG&A growth reflected investments in marketing and field force expansion, as AMLX pivots toward broader clinician engagement. The company maintained profitability and a robust cash position, providing a buffer as it awaits the pivotal Phoenix trial readout in Q2 2024.
- Persistency Drag: Higher discontinuations, not new patient starts, are now the primary limiter of net growth.
- Channel Concentration: Roughly 80 prescribers account for half of all prescriptions, highlighting reliance on ALS centers.
- Inventory and Free Goods: Increase in free drug recipients (now 15%) and steady specialty pharmacy inventory levels slightly diluted revenue realization.
The quarter’s financial outperformance is increasingly dependent on operational execution to address persistency and expand prescriber base, rather than pure demand from ALS specialists.
Executive Commentary
"While we will continue our efforts to grow within these centers, we are now expanding our focus beyond those top centers based on our experience in the field and new research that points to the fact that roughly half of all people living with ALS receive care from clinicians that do not specialize in ALS and are likely unaware of the benefits of Relivrio."
Justin Klee, Co-CEO
"Q3 was helped by a low rate of scrap and the completion of our royalty obligations in the second quarter. Going forward, we expect COGS to be in the range of 5 to 10% of sales... We are well situated as we await the completion of the Phoenix trial."
Jim Friedes, CFO
Strategic Positioning
1. Tackling Discontinuation and Persistency
The US persistency rate for Relivrio is a critical drag on net patient growth, with 40% of patients discontinuing by six months. AMLX is deploying educational initiatives modeled on Canadian best practices, where persistency is 80%, to set expectations and improve duration of therapy. Management sees this as an addressable issue, not an immutable market reality.
2. Expanding Beyond ALS Centers
Nearly half of US ALS patients receive care outside specialty centers, and most non-specialists are not prescribing Relivrio. AMLX is investing in digital outreach, non-personal promotion, and field force optimization to reach these untapped clinicians, viewing this as the next major growth lever.
3. Phoenix Trial as Commercial and Regulatory Catalyst
The upcoming Phoenix trial (664 participants, Q2 2024 readout) is positioned as a watershed moment for both US and international adoption. Positive data would enable rapid EU filing and could drive a step-change in prescriber confidence and patient uptake, especially among non-specialists awaiting confirmatory evidence.
4. Pipeline and Portfolio Diversification
While Relivrio remains the revenue driver, AMLX is advancing AMX35 in progressive supranuclear palsy (PSP) and Wolfram syndrome, and developing next-generation ALS diagnostics and formulations. These programs are in earlier stages but signal a commitment to long-term value creation beyond ALS.
Key Considerations
This quarter marks a shift from launch momentum to operational discipline, with persistency and prescriber expansion now the dominant themes. The company’s ability to translate specialist enthusiasm into broader, durable adoption will define its trajectory through 2024.
Key Considerations:
- Persistency as Growth Lever: Improving duration on therapy is now as important as new patient acquisition.
- Non-Specialist Opportunity: Effective education and outreach to community neurologists could unlock significant incremental demand.
- Phoenix Data as Binary Event: The trial’s outcome will set the pace for both US and ex-US expansion and could reshape the competitive landscape.
- SG&A Discipline: Elevated marketing and personnel costs are necessary investments but must translate to measurable adoption gains.
Risks
High discontinuation rates threaten sustained net patient growth, especially if educational efforts fail to replicate Canadian persistency. Phoenix trial results represent a major binary risk for both commercial momentum and regulatory expansion. The decentralized US care model complicates broad adoption, and increased reliance on free drug programs could pressure realized revenue per patient.
Forward Outlook
For Q4 2023, AMLX expects:
- R&D expenses to rise to $35–40 million as new trials ramp.
- SG&A to remain elevated, reflecting increased marketing and field initiatives.
For full-year 2023, management maintained guidance for:
- Gross-to-net adjustments trending toward 12–15% as free goods and rebates normalize.
Management highlighted several factors that will shape near-term results:
- Steady new patient adds, but net growth is gated by discontinuations.
- Phoenix trial readout in Q2 2024 as the critical inflection for both US and global strategy.
Takeaways
AMLX’s Q3 reveals a business at a crossroads, with initial specialist enthusiasm giving way to the realities of persistency and the need for broader clinician engagement. The outcome of the Phoenix trial will determine whether Relivrio can achieve category-defining penetration or plateau as a niche therapy.
- Persistency is the Core Challenge: The US market’s 40% discontinuation rate at six months sharply contrasts with Canada and must be addressed for durable growth.
- Strategic Expansion Required: Unlocking non-specialist prescribers and improving therapy duration are now the company’s most material levers.
- Phoenix Outcome is Binary: The Q2 2024 readout will dictate global expansion, prescriber confidence, and AMLX’s long-term ALS market share.
Conclusion
AMLX’s early launch success has given way to operational challenges centered on persistency and prescriber breadth. The company’s ability to address these issues, combined with the pivotal Phoenix trial, will define its growth trajectory and value proposition in 2024 and beyond.
Industry Read-Through
AMLX’s experience highlights the critical importance of persistency and clinician education in specialty pharma launches, especially in decentralized US markets. Companies in neurodegeneration and rare disease segments should note the outsized impact of therapy duration on net growth and the need for tailored outreach beyond major centers. The upcoming Phoenix trial will be a bellwether for the ALS field, potentially setting a new standard for evidence and adoption. For biotech peers, binary late-stage readouts remain the ultimate commercial accelerant or reset.